×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Point Of Care Glucose Testing Market Trends

ID: MRFR/HC/10743-HCR
132 Pages
Rahul Gotadki
October 2025

Point Of Care Glucose Testing Market Research Report Information By Product Type (Lancing Devices and Strips and Blood-Glucose Meter), By Application (Type-1 Diabetes and Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Point Of Care Glucose Testing Market Infographic
Purchase Options

Market Trends

Key Emerging Trends in the Point Of Care Glucose Testing Market

The joining of constant glucose observing frameworks into the point of care glucose testing market is driving advancement by upgrading continuous information for improved glycaemic control and patient results. Cell phone associated glucose meters and versatile wellbeing applications that empower clients to screen and examine their glucose levels are on the ascent on the lookout, mirroring the growing job of computerized wellbeing arrangements in diabetes management. The mix of man-made consciousness and AI calculations is affecting the market. These calculations help in proactive diabetes management through the examination of information designs and the arrangement of customized experiences. Point of Care glucose testing is turning out to be progressively preferred in local area and locally established care. It permits people with diabetes to deal with their condition in recognizable conditions, which is reliable with the decentralized medical care development and underscores patient independence in wellbeing management. There is an ongoing business sector pattern towards easy-to-use glucose observing arrangements, including streak frameworks and consistent glucose screens. This pattern means to work on quiet consistence and lessen trouble, at last improving the general client experience in glucose checking. Altogether changing the market for point of care glucose testing is telemedicine and far off persistent reconnaissance in virtual diabetes care. This component empowers medical services experts to remotely assess patient information, working with brief adjustments to therapy designs and empowering constant consideration from the solace of one's own home. As the market shifts toward information availability and interoperability, glucose testing gadgets are turning out to be more flawlessly incorporated with EHRs and medical services data frameworks to work with composed diabetes care. Area of care HbA1c testing is turning out to be all the more generally perceived for its capacity to screen long haul glycaemic control, give experiences into quick and long-haul glycaemic status, and equilibrium constant information in diabetes management. Drug organizations and makers of glucose testing gadgets are teaming up to work on the adequacy of diabetes care through the mix of advances into point of care glucose testing frameworks that convey keen insulin. Endeavours toward normalization and administrative drives are changing the market for point of care glucose testing to guarantee accuracy, reliability, and consistency in diabetes the board methods.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What is the current valuation of the Point Of Care Glucose Testing Market?

The market valuation was 3.531 USD Billion in 2024.

What is the projected market size for the Point Of Care Glucose Testing Market by 2035?

The market is projected to reach 6.105 USD Billion by 2035.

What is the expected CAGR for the Point Of Care Glucose Testing Market during the forecast period 2025 - 2035?

The expected CAGR is 5.1% during the forecast period 2025 - 2035.

Which companies are considered key players in the Point Of Care Glucose Testing Market?

Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, Johnson & Johnson, Siemens Healthineers, Dexcom Inc., Ascensia Diabetes Care, Terumo Corporation, and Nova Biomedical.

What are the main segments of the Point Of Care Glucose Testing Market?

The main segments include Type, Application, and End User.

How did the Blood-Glucose Meter segment perform in 2024?

The Blood-Glucose Meter segment was valued at 2.468 USD Billion in 2024.

Market Summary

As per MRFR analysis, the Point Of Care Glucose Testing Market was estimated at 3.531 USD Billion in 2024. The Point Of Care Glucose Testing industry is projected to grow from 3.712 USD Billion in 2025 to 6.105 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.1 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Point Of Care Glucose Testing Market is experiencing robust growth driven by technological advancements and increasing patient empowerment.

  • Technological advancements in glucose testing devices are enhancing accuracy and user-friendliness, thereby driving market growth. Increased patient empowerment is leading to a higher demand for home testing solutions, particularly in North America. The lancing devices and strips segment remains the largest, while blood-glucose meters are emerging as the fastest-growing segment in the market. Rising prevalence of diabetes and a shift towards home healthcare are key drivers propelling the market forward.

Market Size & Forecast

2024 Market Size 3.531 (USD Billion)
2035 Market Size 6.105 (USD Billion)
CAGR (2025 - 2035) 5.1%
Largest Regional Market Share in 2024 North America

Major Players

<p><a href="https://diagnostics.roche.com/global/en/products/product-category/lab-type/point-of-care-testing-poct/blood-glucose-testing.html">Roche Diagnostics</a> (CH), Abbott Laboratories (US), Bayer AG (DE), Johnson &amp; Johnson (US), Siemens Healthineers (DE), Dexcom Inc. (US), Ascensia Diabetes Care (DE), Terumo Corporation (JP), Nova Biomedical (US)</p>

Market Trends

The Point Of Care Glucose Testing Market is currently experiencing a notable transformation, driven by advancements in technology and an increasing emphasis on patient-centered care. The integration of digital health solutions, such as mobile applications and telemedicine, appears to enhance the accessibility and efficiency of glucose monitoring. This shift is likely to empower patients, enabling them to take charge of their health management. Furthermore, the growing prevalence of diabetes and related conditions is propelling demand for rapid and accurate testing methods, which are essential for timely clinical decisions. As healthcare systems evolve, the Point Of Care Glucose Testing Market is poised to expand, reflecting a broader trend towards decentralized healthcare delivery. In addition, the market seems to be influenced by regulatory changes and the introduction of innovative devices that promise improved accuracy and user-friendliness. Manufacturers are increasingly focusing on developing portable and easy-to-use testing solutions, which could potentially enhance patient compliance and satisfaction. The emphasis on cost-effective healthcare solutions may also drive the adoption of point-of-care testing, as it allows for immediate results and reduces the need for extensive laboratory infrastructure. Overall, the Point Of Care Glucose Testing Market is likely to witness sustained growth, shaped by technological advancements and evolving consumer preferences.

Technological Advancements

The Point Of Care Glucose Testing Market is witnessing rapid technological innovations, with new devices and applications emerging that enhance testing accuracy and user experience. These advancements may lead to more efficient monitoring and management of glucose levels, ultimately benefiting patients.

Increased Patient Empowerment

There is a growing trend towards empowering patients in their healthcare journey. The Point Of Care Glucose Testing Market reflects this shift, as more individuals seek tools that allow them to monitor their health independently, fostering a proactive approach to diabetes management.

Regulatory Support and Innovation

Regulatory bodies are increasingly supporting the development of new testing solutions, which may facilitate the introduction of innovative products in the Point Of Care Glucose Testing Market. This support could encourage manufacturers to invest in research and development, leading to enhanced testing options.

Point Of Care Glucose Testing Market Market Drivers

Rising Prevalence of Diabetes

The increasing prevalence of diabetes worldwide is a primary driver for the Point Of Care Glucose Testing Market. According to recent estimates, the number of individuals diagnosed with diabetes is projected to reach approximately 700 million by 2045. This alarming trend necessitates efficient and accessible glucose monitoring solutions, thereby propelling the demand for point of care testing devices. As healthcare systems strive to manage this chronic condition effectively, the Point Of Care Glucose Testing Market is likely to experience substantial growth. The convenience and immediacy of these testing methods align with the needs of both patients and healthcare providers, fostering a shift towards more decentralized healthcare solutions.

Shift Towards Home Healthcare

The ongoing shift towards home healthcare is reshaping the Point Of Care Glucose Testing Market. Patients increasingly prefer to manage their health conditions from the comfort of their homes, leading to a rise in demand for at-home testing devices. This trend is supported by the growing awareness of diabetes management and the need for regular monitoring. The convenience of home testing not only empowers patients but also reduces the burden on healthcare facilities. As a result, the Point Of Care Glucose Testing Market is likely to see a significant uptick in sales of home-use glucose testing devices, reflecting a broader movement towards personalized healthcare solutions.

Supportive Regulatory Environment

A supportive regulatory environment is fostering innovation and growth within the Point Of Care Glucose Testing Market. Regulatory bodies are increasingly streamlining approval processes for new testing devices, encouraging manufacturers to bring innovative solutions to market. This regulatory support not only enhances the availability of advanced glucose testing technologies but also instills confidence among healthcare providers and patients. As regulations evolve to accommodate new technologies, the Point Of Care Glucose Testing Market is likely to benefit from increased product offerings and improved accessibility, ultimately enhancing patient care and management of diabetes.

Increased Focus on Preventive Healthcare

The heightened emphasis on preventive healthcare is driving growth in the Point Of Care Glucose Testing Market. Healthcare providers are increasingly recognizing the importance of early detection and management of diabetes to prevent complications. This shift is leading to greater investments in point of care testing solutions that facilitate timely interventions. As healthcare systems prioritize preventive measures, the demand for glucose testing devices that can be used in various settings, including clinics and pharmacies, is expected to rise. Consequently, the Point Of Care Glucose Testing Market is poised for expansion as stakeholders seek to enhance patient outcomes through proactive health management.

Technological Innovations in Testing Devices

Technological advancements in glucose testing devices are significantly influencing the Point Of Care Glucose Testing Market. Innovations such as continuous glucose monitoring systems and smartphone-integrated devices enhance user experience and accuracy. These advancements not only improve patient compliance but also facilitate real-time data sharing with healthcare professionals. The market is witnessing a surge in demand for devices that offer rapid results and user-friendly interfaces. As technology continues to evolve, the Point Of Care Glucose Testing Market is expected to expand, driven by the introduction of more sophisticated and efficient testing solutions that cater to the diverse needs of patients.

Market Segment Insights

By Type: Lancing Devices and Strips (Largest) vs. Blood-Glucose Meter (Fastest-Growing)

<p>In the Point Of Care Glucose Testing Market, Lancing Devices and Strips hold a significant share, reflecting their long-standing role in diabetes management. This segment benefits from the steady demand for consumables that work in tandem with glucose meters, providing a reliable means of blood sampling and testing. On the other hand, Blood-Glucose Meters are experiencing rapid growth, fueled by technological advancements and the increasing prevalence of diabetes worldwide. These devices have become more user-friendly and connected, leading to an uptick in adoption rates among patients and healthcare providers alike.</p>

<p>Lancing Devices and Strips (Dominant) vs. Blood-Glucose Meter (Emerging)</p>

<p>Lancing Devices and Strips serve as the backbone of the Point Of Care Glucose Testing Market, showcasing dominance through their essential role in the glucose testing process. These devices are characterized by their reliability and ease of use, providing users with the necessary tools to obtain blood samples for glucose monitoring. Conversely, Blood-Glucose Meters are emerging as a powerhouse segment due to the integration of smart technologies, such as mobile app connectivity and advanced data analytics. These innovations enhance patient engagement and provide healthcare professionals with valuable insights into glucose trends, thereby supporting better patient outcomes. This dynamic is crucial, as the market adapts to the growing demand for efficient and patient-centered diabetes management solutions.</p>

By Application: Type-2 Diabetes (Largest) vs. Type-1 Diabetes (Fastest-Growing)

<p>In the Point Of Care Glucose Testing Market, the distribution of application shares indicates that Type-2 Diabetes holds the largest market share, significantly leading over <a href="https://www.marketresearchfuture.com/reports/type-1-diabetes-treatment-market-8199">Type-1 Diabetes</a>. This dominance is attributed to the higher prevalence of Type-2 Diabetes globally, combined with increasing awareness and screening practices. Healthcare providers are focusing more on Type-2 due to its association with lifestyle factors, which necessitates regular monitoring for effective management and prevention strategies. Conversely, the Type-1 Diabetes segment is experiencing rapid growth, driven by advancements in testing technologies and increased investments in diabetes management. The rise in pediatric and adolescent diagnoses, along with a growing push for personalized healthcare, is further propelling this segment. Initiatives aimed at improving awareness and education around Type-1 Diabetes are also contributing to its accelerated market growth.</p>

<p>Application: Type-2 Diabetes (Dominant) vs. Type-1 Diabetes (Emerging)</p>

<p>The Type-2 Diabetes application in the Point Of Care Glucose Testing Market remains dominant, attracting significant usage due to its vast patient population. Patients often require frequent monitoring, creating consistent demand for testing products. The convenience and accessibility of point-of-care testing align well with the management needs of Type-2 Diabetes patients. On the other hand, the Type-1 Diabetes application, though currently smaller, is emerging rapidly. This segment is characterized by rising incidences among younger populations, requiring tailored testing solutions. The advancements in technology and a growing focus on continuous glucose monitoring systems are positioning Type-1 Diabetes as a crucial part of market growth, with innovative solutions catering to the unique needs of these patients.</p>

By End User: Hospitals and Clinics (Largest) vs. Home Care Settings (Fastest-Growing)

<p>In the Point Of Care Glucose Testing Market, the end-user segment is primarily dominated by Hospitals and Clinics, which account for a significant portion of market share. This preference can be attributed to the high volume of routine glucose monitoring required in clinical settings where patient management is critical. On the other hand, Home Care Settings are gaining traction, reflecting a shift towards patient-centric care and the growing demand for at-home monitoring solutions, especially with the rise of chronic diseases such as diabetes.</p>

<p>End User: Hospitals and Clinics (Dominant) vs. Home Care Settings (Emerging)</p>

<p>Within the Point Of Care Glucose Testing Market, Hospitals and Clinics emerge as the dominant end-users due to their extensive infrastructure and need for accurate and immediate glucose readings to make timely clinical decisions. These facilities typically have sophisticated testing modalities and skilled personnel optimizing their testing processes. On the contrary, Home Care Settings are classified as an emerging segment, driven by the increasing trend of self-monitoring among patients, coupled with advancements in accessible technology. As diabetes management continues to shift towards decentralized care, home testing devices are becoming essential for empowering patients, ultimately leading to improved outcomes.</p>

Get more detailed insights about Point Of Care Glucose Testing Market Research Report 2035

Regional Insights

North America : Healthcare Innovation Leader

North America is the largest market for Point Of Care Glucose Testing Market, holding approximately 45% of the global share. The region's growth is driven by increasing diabetes prevalence, technological advancements, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for new devices, enhancing market dynamics. The demand for rapid testing solutions in both clinical and home settings is also on the rise, further propelling market growth. The United States leads the North American market, followed by Canada. Major players such as Abbott Laboratories, Johnson & Johnson, and Dexcom Inc. are heavily investing in R&D to innovate and expand their product lines. The competitive landscape is characterized by strategic partnerships and collaborations aimed at enhancing product offerings. The presence of advanced healthcare infrastructure and a high rate of diabetes awareness contribute to the region's market strength.

Europe : Emerging Market with Regulations

Europe is the second-largest market for Point Of Care Glucose Testing Market, accounting for around 30% of the global market share. The region's growth is driven by increasing diabetes cases, an aging population, and a shift towards decentralized healthcare. Regulatory frameworks, such as the EU Medical Device Regulation, are enhancing product safety and efficacy, thereby boosting consumer confidence and market demand. The emphasis on preventive healthcare is also a significant driver of growth in this sector. Germany, France, and the UK are the leading countries in this market, with Germany holding the largest share. Key players like Roche Diagnostics and Siemens Healthineers are focusing on innovation and expanding their product portfolios. The competitive landscape is marked by collaborations between manufacturers and healthcare providers to improve patient outcomes. The presence of a robust healthcare system and increasing investments in health technology further support market expansion.

Asia-Pacific : Rapidly Growing Market

Asia-Pacific is witnessing rapid growth in the Point Of Care Glucose Testing Market, holding approximately 20% of the global share. The region's growth is fueled by rising diabetes prevalence, increasing healthcare expenditure, and a growing focus on preventive healthcare. Countries like India and China are experiencing significant demand for glucose testing devices due to their large diabetic populations. Government initiatives aimed at improving healthcare access are also contributing to market expansion. China and India are the leading countries in this region, with a growing number of local and international players entering the market. Companies like Terumo Corporation and Nova Biomedical are expanding their presence through strategic partnerships and localized manufacturing. The competitive landscape is evolving, with an increasing emphasis on affordability and accessibility of testing solutions to cater to the diverse population needs.

Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region represents an emerging market for Point Of Care Glucose Testing Market, holding about 5% of the global share. The growth is driven by increasing diabetes prevalence, rising healthcare investments, and a growing awareness of diabetes management. However, challenges such as limited healthcare infrastructure and regulatory hurdles can impede market growth. Governments are increasingly recognizing the importance of diabetes care, leading to initiatives aimed at improving healthcare access and quality. South Africa and the UAE are the leading markets in this region, with a growing number of international players entering the landscape. Companies are focusing on establishing partnerships with local healthcare providers to enhance distribution and accessibility. The competitive environment is characterized by a mix of global and regional players, with an emphasis on affordable testing solutions to meet the needs of diverse populations.

Key Players and Competitive Insights

The Point Of Care Glucose Testing Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of diabetes globally. Key players such as Roche Diagnostics (Switzerland), Abbott Laboratories (US), and Dexcom Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche Diagnostics (Switzerland) focuses on innovation, particularly in developing integrated systems that combine glucose monitoring with data management solutions. Abbott Laboratories (US) emphasizes regional expansion, particularly in emerging markets, to capture a broader customer base. Meanwhile, Dexcom Inc. (US) is heavily investing in digital transformation, leveraging data analytics to improve patient outcomes and streamline operations. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and patient-centric solutions.

In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that significantly influence trends and pricing. This competitive structure allows for a diverse range of products and services, catering to various consumer needs while fostering innovation through competition.

In August 2025, Abbott Laboratories (US) announced the launch of its latest continuous glucose monitoring system, which integrates seamlessly with mobile health applications. This strategic move not only enhances user experience but also positions Abbott as a leader in digital health solutions, potentially increasing its market share in the rapidly evolving landscape of diabetes management. The integration of mobile technology into glucose monitoring is likely to attract tech-savvy consumers, thereby expanding Abbott's customer base.

In September 2025, Roche Diagnostics (Switzerland) unveiled a new partnership with a leading telehealth provider to offer remote glucose monitoring services. This collaboration is strategically significant as it aligns with the growing trend of telemedicine, allowing Roche to tap into a broader market segment that prioritizes convenience and accessibility. By integrating their testing solutions with telehealth services, Roche is likely to enhance patient engagement and adherence to treatment protocols.

In October 2025, Dexcom Inc. (US) revealed advancements in its artificial intelligence algorithms designed to predict glucose fluctuations more accurately. This development is crucial as it not only improves the reliability of glucose monitoring but also positions Dexcom at the cutting edge of technology in diabetes management. The ability to provide predictive insights could significantly enhance patient outcomes, thereby solidifying Dexcom's competitive advantage in the market.

As of October 2025, current trends in the Point Of Care Glucose Testing Market indicate a strong shift towards digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage complementary strengths and enhance their product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of developing robust, patient-centric solutions that not only meet regulatory standards but also address the evolving needs of consumers.

Key Companies in the Point Of Care Glucose Testing Market market include

Industry Developments

  • Q2 2024: Abbott launches next-generation FreeStyle Libre 4 continuous glucose monitor in Europe Abbott announced the commercial launch of its FreeStyle Libre 4, a next-generation continuous glucose monitoring system, in select European markets. The device features enhanced accuracy and new connectivity features for point-of-care and home use.
  • Q2 2024: Dexcom Receives FDA Clearance for G7 Continuous Glucose Monitoring System for Hospital Point-of-Care Use Dexcom announced that the U.S. FDA has cleared its G7 continuous glucose monitoring system for use in hospital point-of-care settings, expanding its application beyond personal diabetes management.
  • Q1 2024: Roche launches Accu-Chek Instant Connect, a Bluetooth-enabled point-of-care glucose meter Roche introduced the Accu-Chek Instant Connect, a new Bluetooth-enabled glucose meter designed for rapid point-of-care testing and seamless integration with electronic health records in clinical settings.
  • Q2 2024: Ascensia Diabetes Care and Glooko Announce Partnership to Integrate Point-of-Care Glucose Data with Digital Diabetes Management Platform Ascensia Diabetes Care entered a partnership with Glooko to integrate data from its point-of-care glucose meters into Glooko’s digital diabetes management platform, enabling real-time data sharing between patients and healthcare providers.
  • Q3 2024: Trividia Health Receives CE Mark for TRUE METRIX AIR Professional Point-of-Care Glucose Meter Trividia Health announced it has received CE Mark approval for its TRUE METRIX AIR Professional, a new point-of-care glucose meter intended for use in hospitals and clinics across Europe.
  • Q1 2024: PTS Diagnostics Launches New Point-of-Care Glucose and HbA1c Analyzer in the U.S. PTS Diagnostics launched a new combined glucose and HbA1c analyzer for point-of-care use in the United States, targeting primary care clinics and community health centers.
  • Q2 2024: BioIntelliSense raises $45M Series B to expand wearable point-of-care glucose monitoring platform BioIntelliSense secured $45 million in Series B funding to accelerate the development and commercialization of its wearable point-of-care glucose monitoring platform for both hospital and home settings.
  • Q2 2024: Siemens Healthineers acquires GlySure, expanding point-of-care glucose monitoring portfolio Siemens Healthineers completed the acquisition of GlySure, a company specializing in continuous intravascular glucose monitoring, to strengthen its point-of-care diagnostics offerings.
  • Q3 2024: Nova Biomedical Opens New Manufacturing Facility for StatStrip Glucose Hospital Meters Nova Biomedical opened a new manufacturing facility dedicated to producing its StatStrip point-of-care glucose meters for hospital use, aiming to meet growing demand in North America and Europe.
  • Q2 2025: AgaMatrix Receives FDA 510(k) Clearance for WaveSense Jazz Wireless Pro Point-of-Care Glucose Meter AgaMatrix announced it has received FDA 510(k) clearance for its WaveSense Jazz Wireless Pro, a new point-of-care glucose meter designed for professional healthcare settings.
  • Q1 2025: EKF Diagnostics Launches STAT-Site WB Pro, a New Point-of-Care Glucose and Ketone Analyzer EKF Diagnostics launched the STAT-Site WB Pro, a new analyzer capable of measuring both glucose and ketone levels at the point of care, targeting emergency and critical care environments.
  • Q2 2025: Medtronic Announces Partnership with Microsoft to Develop AI-Driven Point-of-Care Glucose Monitoring Solutions Medtronic entered a partnership with Microsoft to co-develop artificial intelligence-powered solutions for point-of-care glucose monitoring, aiming to enhance clinical decision support and patient outcomes.

Future Outlook

Point Of Care Glucose Testing Market Future Outlook

<p>The Point Of Care Glucose Testing Market is projected to grow at a 5.1% CAGR from 2024 to 2035, driven by technological advancements, increasing diabetes prevalence, and demand for rapid testing solutions.</p>

New opportunities lie in:

  • <p>Development of portable glucose monitoring devices for home use.</p>
  • <p>Integration of AI analytics for personalized diabetes management.</p>
  • <p>Expansion of telehealth services for remote glucose monitoring.</p>

<p>By 2035, the market is expected to be robust, driven by innovation and increased accessibility.</p>

Market Segmentation

Point Of Care Glucose Testing Market Type Outlook

  • Lancing Devices and Strips
  • Blood-Glucose Meter

Point Of Care Glucose Testing Market End User Outlook

  • Hospitals and Clinics
  • Home Care Settings
  • Others

Point Of Care Glucose Testing Market Application Outlook

  • Type-1 Diabetes
  • Type-2 Diabetes

Report Scope

MARKET SIZE 2024 3.531(USD Billion)
MARKET SIZE 2025 3.712(USD Billion)
MARKET SIZE 2035 6.105(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.1% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Market analysis in progress
Segments Covered Market segmentation analysis in progress
Key Market Opportunities Integration of advanced digital health technologies enhances patient engagement in the Point Of Care Glucose Testing Market.
Key Market Dynamics Technological advancements and regulatory changes drive innovation and competition in the Point Of Care Glucose Testing Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Point Of Care Glucose Testing Market?

The market valuation was 3.531 USD Billion in 2024.

What is the projected market size for the Point Of Care Glucose Testing Market by 2035?

The market is projected to reach 6.105 USD Billion by 2035.

What is the expected CAGR for the Point Of Care Glucose Testing Market during the forecast period 2025 - 2035?

The expected CAGR is 5.1% during the forecast period 2025 - 2035.

Which companies are considered key players in the Point Of Care Glucose Testing Market?

Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, Johnson &amp; Johnson, Siemens Healthineers, Dexcom Inc., Ascensia Diabetes Care, Terumo Corporation, and Nova Biomedical.

What are the main segments of the Point Of Care Glucose Testing Market?

The main segments include Type, Application, and End User.

How did the Blood-Glucose Meter segment perform in 2024?

The Blood-Glucose Meter segment was valued at 2.468 USD Billion in 2024.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    2. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS
    1. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    2. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. Healthcare, BY Type (USD Billion)
      1. Lancing Devices and Strips
      2. Blood-Glucose Meter
    2. Healthcare, BY Application (USD Billion)
      1. Type-1 Diabetes
      2. Type-2 Diabetes
    3. Healthcare, BY End User (USD Billion)
      1. Hospitals and Clinics
      2. Home Care Settings
      3. Others
    4. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    2. Company Profiles
      1. Roche Diagnostics (CH)
      2. Abbott Laboratories (US)
      3. Bayer AG (DE)
      4. Johnson & Johnson (US)
      5. Siemens Healthineers (DE)
      6. Dexcom Inc. (US)
      7. Ascensia Diabetes Care (DE)
      8. Terumo Corporation (JP)
      9. Nova Biomedical (US)
    3. Appendix
      1. References
      2. Related Reports 6 LIST OF FIGURES
    4. MARKET SYNOPSIS
    5. NORTH AMERICA MARKET ANALYSIS
    6. US MARKET ANALYSIS BY TYPE
    7. US MARKET ANALYSIS BY APPLICATION
    8. US MARKET ANALYSIS BY END USER
    9. CANADA MARKET ANALYSIS BY TYPE
    10. CANADA MARKET ANALYSIS BY APPLICATION
    11. CANADA MARKET ANALYSIS BY END USER
    12. EUROPE MARKET ANALYSIS
    13. GERMANY MARKET ANALYSIS BY TYPE
    14. GERMANY MARKET ANALYSIS BY APPLICATION
    15. GERMANY MARKET ANALYSIS BY END USER
    16. UK MARKET ANALYSIS BY TYPE
    17. UK MARKET ANALYSIS BY APPLICATION
    18. UK MARKET ANALYSIS BY END USER
    19. FRANCE MARKET ANALYSIS BY TYPE
    20. FRANCE MARKET ANALYSIS BY APPLICATION
    21. FRANCE MARKET ANALYSIS BY END USER
    22. RUSSIA MARKET ANALYSIS BY TYPE
    23. RUSSIA MARKET ANALYSIS BY APPLICATION
    24. RUSSIA MARKET ANALYSIS BY END USER
    25. ITALY MARKET ANALYSIS BY TYPE
    26. ITALY MARKET ANALYSIS BY APPLICATION
    27. ITALY MARKET ANALYSIS BY END USER
    28. SPAIN MARKET ANALYSIS BY TYPE
    29. SPAIN MARKET ANALYSIS BY APPLICATION
    30. SPAIN MARKET ANALYSIS BY END USER
    31. REST OF EUROPE MARKET ANALYSIS BY TYPE
    32. REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    33. REST OF EUROPE MARKET ANALYSIS BY END USER
    34. APAC MARKET ANALYSIS
    35. CHINA MARKET ANALYSIS BY TYPE
    36. CHINA MARKET ANALYSIS BY APPLICATION
    37. CHINA MARKET ANALYSIS BY END USER
    38. INDIA MARKET ANALYSIS BY TYPE
    39. INDIA MARKET ANALYSIS BY APPLICATION
    40. INDIA MARKET ANALYSIS BY END USER
    41. JAPAN MARKET ANALYSIS BY TYPE
    42. JAPAN MARKET ANALYSIS BY APPLICATION
    43. JAPAN MARKET ANALYSIS BY END USER
    44. SOUTH KOREA MARKET ANALYSIS BY TYPE
    45. SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    46. SOUTH KOREA MARKET ANALYSIS BY END USER
    47. MALAYSIA MARKET ANALYSIS BY TYPE
    48. MALAYSIA MARKET ANALYSIS BY APPLICATION
    49. MALAYSIA MARKET ANALYSIS BY END USER
    50. THAILAND MARKET ANALYSIS BY TYPE
    51. THAILAND MARKET ANALYSIS BY APPLICATION
    52. THAILAND MARKET ANALYSIS BY END USER
    53. INDONESIA MARKET ANALYSIS BY TYPE
    54. INDONESIA MARKET ANALYSIS BY APPLICATION
    55. INDONESIA MARKET ANALYSIS BY END USER
    56. REST OF APAC MARKET ANALYSIS BY TYPE
    57. REST OF APAC MARKET ANALYSIS BY APPLICATION
    58. REST OF APAC MARKET ANALYSIS BY END USER
    59. SOUTH AMERICA MARKET ANALYSIS
    60. BRAZIL MARKET ANALYSIS BY TYPE
    61. BRAZIL MARKET ANALYSIS BY APPLICATION
    62. BRAZIL MARKET ANALYSIS BY END USER
    63. MEXICO MARKET ANALYSIS BY TYPE
    64. MEXICO MARKET ANALYSIS BY APPLICATION
    65. MEXICO MARKET ANALYSIS BY END USER
    66. ARGENTINA MARKET ANALYSIS BY TYPE
    67. ARGENTINA MARKET ANALYSIS BY APPLICATION
    68. ARGENTINA MARKET ANALYSIS BY END USER
    69. REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    70. REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    71. REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    72. MEA MARKET ANALYSIS
    73. GCC COUNTRIES MARKET ANALYSIS BY TYPE
    74. GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    75. GCC COUNTRIES MARKET ANALYSIS BY END USER
    76. SOUTH AFRICA MARKET ANALYSIS BY TYPE
    77. SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    78. SOUTH AFRICA MARKET ANALYSIS BY END USER
    79. REST OF MEA MARKET ANALYSIS BY TYPE
    80. REST OF MEA MARKET ANALYSIS BY APPLICATION
    81. REST OF MEA MARKET ANALYSIS BY END USER
    82. KEY BUYING CRITERIA OF HEALTHCARE
    83. RESEARCH PROCESS OF MRFR
    84. DRO ANALYSIS OF HEALTHCARE
    85. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    86. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    87. SUPPLY / VALUE CHAIN: HEALTHCARE
    88. HEALTHCARE, BY TYPE, 2024 (% SHARE)
    89. HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    90. HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    91. HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    92. HEALTHCARE, BY END USER, 2024 (% SHARE)
    93. HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    94. BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES
    95. LIST OF ASSUMPTIONS
    96. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    97. US MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    98. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    99. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    100. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    101. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    102. France MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    103. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    104. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    105. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    106. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    107. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    108. China MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    109. India MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    110. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    111. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    112. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    113. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    114. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    115. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    116. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    117. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    118. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    119. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    120. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    121. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    122. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    123. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    124. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY TYPE, 2025-2035 (USD Billion)
      2. BY APPLICATION, 2025-2035 (USD Billion)
      3. BY END USER, 2025-2035 (USD Billion)
    125. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    126. ACQUISITION/PARTNERSHIP

Point Of Care Glucose Testing Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions